Selected Laboratory Team Publications

1. Hernandez-Ilizaliturri, F.J., et al., Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res, 2003. 9(16 Pt 1): p. 5866-73.

2. Czuczman, M. and P.L. Zinzani, The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments. Leuk Lymphoma, 2003. 44 Suppl 3: p. S1-4.

3. Hernandez-Ilizaliturri, F.J., A. Gowda, and M.S. Czuczman, Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Clin Adv Hematol Oncol, 2004. 2(9): p. 606-18.

4. Ramanarayanan, J., et al., Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol, 2004. 127(5): p. 519-30.

5. Hernandez-Ilizaliturri, F.J., et al., Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol, 2004. 27(1): p. 68-72.

6. Hernandez-Ilizaliturri, F.J., et al., Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma, 2005. 46(12): p. 1775-84.

7. Hernandez-Ilizaliturri, F.J., et al., Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res, 2005. 11(16): p. 5984-92.

8. Czuczman, M.S., et al., Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol, 2005. 23(4): p. 694-704.

9. Czuczman, M.S., et al., Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol, 2005. 23(19): p. 4390-8.

10. Chanan-Khan, A., et al., Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol, 2006. 24(34): p. 5343-9.

11. Hoppe, R.T., et al., Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2006. 4(3): p. 210-30.

12. Chadha, K.S., F.J. Hernandez-Ilizaliturri, and M. Javle, Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci, 2006. 51(1): p. 77-83.

13. Olejniczak, S.H., et al., A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest, 2006. 35(1): p. 93-114.

14. Maddipatla, S., et al., Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res, 2007. 13(15 Pt 1): p. 4556-64.

15. Czuczman, M.S., et al., Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol, 2007. 25(27): p. 4285-92.

16. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, and Czuczman MS. Immunomodulatory drugs (IMiDs) lenalidomide and actimid stimulate NK-cell function, alter cytokine production by Dendritic Cells (DC’s), and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. The British Journal of Hematology 2007 (In press)

17. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans JP, and Hernandez-Ilizaliturri FJ. Acquirement of Rituximab Resistance in Lymphoma Cell Lines is Associated with Both a Global CD20 Gene and Protein Down-Regulation Regulated at the Pre- and Post-Transcriptional Level. Clinical Cancer Research 2007; (In Press).

18. Cruz R, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, and Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity (CMC) but not antibody-dependent cellular cytotoxicity (ADCC): Pre-clinical evidence targeting CD52 with alemtuzumab to reverse acquired resistance to rituximab in Non-Hodgkin’s Lymphoma (NHL) Leukemia and Lymphoma 2007; (In press).